This reference hub prioritizes regulatory authorities, official prescribing information and peer-reviewed clinical evidence.
Regulatory Sources
U.S. Food and Drug Administration
FDA approval records provide current U.S. regulatory information for selpercatinib, including recent traditional approvals for RET-positive thyroid cancer, medullary thyroid cancer and RET fusion-positive solid tumors.
DailyMed
DailyMed provides the current U.S. RETEVMO label, including dosage forms, indications, warnings, adverse reactions, interactions and pharmacology. The current version is effective July 14, 2026.
European Medicines Agency
The EMA Retsevmo EPAR provides European authorization information and product details. The current EPAR was updated in July 2026.
Clinical literature
Important clinical evidence includes LIBRETTO-001, LIBRETTO-431 and LIBRETTO-531.
Manufacturer and developer information
Current Lilly resources identify Retevmo as a Lilly medicine. FDA records document Loxo Oncology as the original sponsor in the early development and approval history.
Selcaxen-specific documentation
The manufacturer, authorization status and official product documentation for Selcaxen 40 mg are: Everest Pharmaceuticals Ltd.